Wedbush downgraded Astria Therapeutics (ATXS) to Neutral from Outperform with a price target of $13, down from $28, after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- BioCryst price target raised to $27 from $17 at Citizens JMP
- Astria downgraded to Market Perform from Outperform at Citizens JMP
- BioCryst reinstated with a Buy at TD Cowen
- Astria Therapeutics downgraded to Perform from Outperform at Oppenheimer
- BioCryst weakness presents ‘compelling’ buying opportunity, says RBC